Physician profile
Maritza Harrison
NPI 1114237104
$2,564.25
in general payments reported to CMS, 2019-2025
18 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $424 · 2022: $814 · 2023: $737 · 2024: $234 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $652.82 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $408.79 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $367.94 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $278.60 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $268.97 | 2021-2022 | |
| Glaxosmithkline, LLC. | $123.32 | 2023 | Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $101.41 | 2022 | |
| Lilly USA, LLC | $74.02 | 2021-2024 | Mounjaro |
| Boston Scientific Corporation | $68.46 | 2023 | Wavewriter Alpha Prime 16 |
| Xeris Pharmaceuticals, INC. | $42.93 | 2022-2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.91 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $28.45 | 2021 | |
| Abbvie INC. | $21.75 | 2024 | |
| Scilex Pharmaceuticals INC. | $21.30 | 2022 | |
| Si-Bone, INC. | $20.83 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $18.12 | 2023 | Rexulti |
| Exact Sciences Corporation | $16.22 | 2025 | Cologuard Collection Kit |
| Cequr Corporation | $15.41 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maritza Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.